Sponsored Links

HEADLINE STOCKS-U.S. small/midcap stocks to watch on March 9

Related Topics

Tue Mar 9, 2010 8:53am EST

(For large-cap stocks to watch, click on [WATCH/US])

March 9 (Reuters) - Some small and midcap stocks to watch on Tuesday:

JONES SODA CO JSDA.O, $0.50, down 40 pct

The struggling soft drink maker signed a letter of intent to be acquired by Reeds Inc REED.O in a cash-and-stock deal worth about $9.7 million. [ID:nSGE6280ED]

CERUS CORP (CERS.O), $2.67, up 13 pct

Robert W. Baird upgraded the blood safety products maker to "outperform" from "neutral," and said the market is undervaluing the company's Intercept red blood cell system. [ID:SGE6280GY]

SUSQUEHANNA BANCSHARES INC (SUSQ.O), $8.61, down 5 pct

The company on Monday said it will offer common shares to raise $300 million partly to support future acquisitions, including FDIC-assisted acquisition transactions or to pay back U.S. Treasury's funds. [ID:nSGE6270L0]

AGFEED INDUSTRIES INC FEED.O, $5.30, up 18 pct

The company reported better-than-expected full-year earnings helped by increased production volumes in the company's hog division and animal nutrition divisions. [ID:nWNAB6928]

MICROVISION INC (MVIS.O), $2.55, down 10 pct

The portable projector maker on Monday posted a narrower quarterly loss that was in line with analysts' view, but revenue fell short of market expectations. [ID:nSGE6270LL]

IMMUNOGEN INC (IMGN.O), $7.68, up 4 pct

The drugmaker said on Monday its experimental skin cancer drug received orphan drug designation from U.S. and European health regulators. [ID:nSGE6270L7]

EXELIXIS INC (EXEL.O), $6.81, Monday's close

The cancer drug developer posted a quarterly loss in line with market expectations, and forecast a full-year revenue above consensus estimates. [ID:SGE6280F5]

MATRIXX INITIATIVES MTXX.O, $4.87, Monday's close

The pharmaceuticals company said U.S. health regulators declined to withdraw the warning letter on the company's nasal versions of Zicam cold remedy. [ID:SGE6280EX] (Reporting by Mansi Dutta in Bangalore)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.